Renewed Agreement Accelerates Vaccine Candidates Against Emerging Infectious Diseases

The Coalition for Epidemic Preparedness Innovations (CEPI) and the International Vaccine Institute (IVI) recently renewed a multi-year collaboration to accelerate the development of vaccines against emerging infectious diseases.

Under the renewed CEPI-IVI Implementing Partnership Agreement announced on September 1, 2023, IVI will provide technical services for CEPI-funded projects, leveraging IVI’s expertise and capabilities at their headquarters in Korea.

And help accelerate vaccine development against pathogens with epidemic or pandemic potential, and in support of CEPI’s 100 Days Mission, a goal to reduce the time taken to develop safe and effective vaccines against pathogens with pandemic potential to 100 days.

To this end, IVI will support CEPI across a variety of projects, including providing strategic, technical, and scientific support for clinical development and manufacturing of vaccines, standards, and assay development, and capacity-building initiatives that strengthen local resources to help establish or improve research preparedness and emergency evidence generation for future outbreaks.

CEPI's 5-year plan lays out a $3.5 billion roadmap to compress vaccine development timelines to 100 days, develop a broadly protective vaccine against COVID-19 and other betacoronaviruses, and create a "library" of vaccine candidates for use against known and unknown pathogens.

CEPI has also invested in new platform technologies for rapid vaccine development against unknown pathogens (Disease X).

Before the recent pandemic, beginning in 2027, CEPI focused on developing vaccines against the Ebola, Lassa, MERS, Nipah, Rift Valley Fever, and Chikungunya viruses. 

CEPI's plan is available at https://endpandemics.cepi.net.